BioAtla, Inc. (BCAB) vs Calidi Biotherapeutics, Inc. (CLDI)

BioAtla, Inc. and Calidi Biotherapeutics, Inc. are both Biotechnology companies. BioAtla, Inc. and Calidi Biotherapeutics, Inc. are of similar size ($3.0M and $2.9M). Calidi Biotherapeutics, Inc. has the higher net margin (0.00% vs −177.2%) and the higher return on invested capital (0.00% vs 0.00%). Across the 11 metrics below, BioAtla, Inc. leads on 6 and Calidi Biotherapeutics, Inc. on 5.

Valuation

Metric BCAB CLDI Biotechnology median
P/E n/m n/m 7.88
P/S 0.14 n/m 11.47
P/B n/m 0.51 2.52
Price to free cash flow n/m n/m 21.16
EV/EBITDA n/m 0.04 0.74
EV/Sales 0.21 n/m 10.73
Earnings yield (1,719.59%) (4,805.31%) (28.84%)
Free cash flow yield (959.44%) (1,115.26%) (23.03%)

Profitability

Metric BCAB CLDI Biotechnology median
Gross margin 95.44% — 65.16%
Operating margin (180.99%) 0.00% 0.00%
Net margin (177.21%) 0.00% 0.00%
Free cash flow margin (132.29%) 0.00% 0.00%
Return on equity 118.74% (900.56%) (57.72%)
Return on assets (171.72%) (283.36%) (49.22%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric BCAB CLDI Biotechnology median
Revenue growth (TTM) 574.65% — 5.64%
EPS growth (last fiscal year) 29.86% 83.31% —
Revenue growth, 5-year CAGR (28.40%) — 8.40%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric BCAB CLDI Biotechnology median
Debt to equity 0.00 0.24 0.00
Current ratio 0.20 1.68 4.73
Net debt to EBITDA 0.12 0.26 0.96

Dividend

Metric BCAB CLDI Biotechnology median
Dividend yield — — 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric BCAB CLDI Biotechnology median
Market cap 2.89m 2.97m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack